CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel ) in Autoimmune Diseases and Hematologic Malignancies
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Editing Platform
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy 2025 Annual Congress
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association Scientific Sessions 2025
Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
Copper Quest Announces 2026 Exploration Programs Beginning with Drilling on the Rip Copper-Molybdenum Project
SAGA Metals Reports Assays from R-0024 to R-0026 with Intercepts Including 54.20% Fe2O3, 7.07% TiO2, 0.443% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
CHARBONE Advances Strategic Expansion in Malaysia and Confirms Intent to Participate and Operate in Green Hydrogen ASIAPAC
